Theranica Bio-Electronics

Founded in 2016 and headquartered in Netanya, Israel, Theranica Bio-Electronics specializes in wearable medical devices., Shimon Eckhouse, and Slava Barabash.Theranica Bio-Electronics specializes in drug-free pain relief through its flagship product, Nerivio, a novel wearable device designed for the management of migraine and other neurological pain conditions. Nerivio utilizes remote electrical neuromodulation (REN) to stimulate peripheral nerves in the upper arm, effectively triggering Conditioned Pain Modulation (CPM) to enhance the brain's ability to inhibit pain perception. The company markets its products primarily to patients and healthcare providers across North America, Europe, and select markets in Asia, targeting demographics affected by chronic pain conditions, particularly those seeking non-pharmacological treatment options.Theranica's revenue model is centered around direct-to-consumer sales of its Nerivio device, which requires a prescription from healthcare providers. The company collaborates with medical professionals and institutions to provide access to its products. Each transaction involves healthcare providers recommending Nerivio to patients, who then purchase the device either directly or through designated retail channels. The pricing structure for Nerivio is designed to be accessible, reflecting the company's aim to offer affordable pain management solutions. The company is also focused on designing and launching new products, although specific release dates have not been disclosed.

1. Series C

   Aug 29, 2022

   Amount

   $45M

   Investors

   Locked

2. Series B

   Mar 18, 2019

   Amount

   $35M

   Investors

   Locked

3. Series A

   Jul 3, 2017

   Amount

   $6M

   Investors

   Locked